Financial Performance (Q1 FY27 vs Q1 FY26)

  • Revenue: ₹422 crores vs ₹347 crores, growth of 21.9% YoY
  • Revenue growth excluding acquired portfolio (Wokadine): 21.4%
  • India business revenue contribution: 97%
  • India business revenue growth: 22.7% YoY
  • EBITDA: ₹93 crores vs ₹70 crores, growth of 33.5% YoY
  • EBITDA margin: 22% (improved 190 bps YoY)
  • Profit After Tax: ₹60 crores vs ₹46 crores, growth of 30.1% YoY
  • PAT margin: 14.2% (improved 90 bps YoY)
  • Chronic segment contribution: 73.4% of total portfolio
  • Depreciation & Amortization: ₹13.4 crores vs ₹10 crores in Q1 FY26

Operational Highlights

  • The Indian Pharmaceutical Market (IPM) has shown sustained double-digit growth of over 10% since December 2025
  • Corona improved its IPM ranking from 29th to 26th position over the past year
  • Growth drivers as per MAT June 2026 PharmaTrac data:
  • Volume growth: 6.3% (vs IPM 1.3%)
  • Price growth: 8.7% (vs IPM 5.6%)
  • New product introduction: 3.4% (vs IPM 2.9%)

Therapeutic Area Performance

  • Women's Healthcare: 23.3% growth (vs IPM 9.4%)
  • Urology: 27.6% growth (vs IPM 14.9%)
  • Cardio-Diabeto: Outperformed market by 1.7x
  • Pain Management: Outperformed market by 1.4x

Brand Portfolio Development

  • Number of brands with annual revenues exceeding ₹100 crores: 2 (increased from 1 in MAT June 2023)
  • Number of brands with annual revenues exceeding ₹10 crores: Over 40 (increased from 32 in MAT June 2023)

Manufacturing Updates

  • Successfully commercialized India's most advanced Europe-GMP approved Women's hormone manufacturing facility
  • Facility enables manufacturing of complex hormonal products meeting global quality standards
  • Houses multiple dosage forms including tablets, soft gelatin capsules, ointment and gels
  • Designed to serve niche segments including hormonal disorders, fertility care, menopause management and hormonal replacement therapy
  • Europe-GMP certification renewed for Ahmedabad oral solid dosage form facility

Strategic Initiatives

  • Successfully integrated Wokadine acquisition (completed on last day of FY26)
  • Established dedicated IVF task force focused on Gynecology and Women's Healthcare
  • Realigned field force structure
  • Strengthening R&D focus with investments in process efficiencies, differentiated formulations, and new product opportunities
  • Augmenting R&D team with new talent

Capital Allocation and Investments

  • Hormonal facility capex: ₹130 crores
  • Wokadine acquisition cost: ₹97 crores plus GST
  • Bayer brand acquisition cost: ₹7 crores
  • In-house manufacturing share: 60% (40% outsourced)

Guidance and Outlook

  • FY27 guidance unchanged: 15% organic revenue growth, 1.5-2% inorganic growth, 20% PAT growth
  • Medium-term target: Outperform IPM by 500 basis points
  • Wokadine brand target: 25% growth for next three years (from ₹20 crores to ₹40 crores)
  • Field force expansion: 6-8% annual addition (200-250 medical representatives)
  • International business expected to grow from current 3% to higher single digits over 3-5 years

Management Commentary

The management expressed confidence in sustaining growth momentum through:

  • Expanding market share across core therapy areas
  • Focused new product launches addressing unmet patient needs
  • Brand acquisition and in-licensing opportunities
  • Deepening engagement with specialists and super-specialists
  • Disciplined capital allocation

Risk Factors Mentioned

  • Geopolitical risks in Southeast Asia affecting raw material prices
  • Volatile input and ancillary cost environment
  • Expected raw material cost impact of approximately 100 basis points in coming quarters

Q&A Session Key Points

  • Hormonal facility expected to achieve turnover ratio of 1x in FY27, growing to 2-3x over three years
  • International dossiers from new facility expected to be ready by November-December 2026, with business commencing in FY28-29
  • Employee costs remain elevated due to deployment of 1,000 medical reps over last 3.5 years (total field force: 3,111)
  • La Chandra Pharma Lab (31% associate company) provides 60-65% of hormonal API requirements
  • Bayer-Zydus portfolio generated ₹7 crores revenue in Q1, matching acquisition cost
  • Depreciation impact from hormonal facility: ~₹6.5 crores annually (20-year depreciation)
  • Amortization of Wokadine: ~₹10 crores annually (10-year amortization)